In a pandemic, there is no time to waste. One way to speed the process of delivering safe, effective antiviral treatments is to put old drugs to work against the new disease threat. Calibr, the drug development division of Scripps Research, is doing just that with ReFRAME, its library of over 14,000 FDA-approved compounds, including drugs already being repurposed for numerous diseases. With cutting-edge, robotic screening technologies and this valuable collection, Calibr researchers are proving that what’s old can be new again.